Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
Diabetes Obes Metab. 2024 Sep;26(9):3958-3968. doi: 10.1111/dom.15744. Epub 2024 Jul 4.
Dysglycaemia accelerates cognitive decline. Intensive glucose control may help delay or prevent cognitive function decline (CFD). We aimed to determine how patient characteristics influence the effect of intensive glucose control [glycated haemoglobin (HbA1c) <6.0%] on delaying CFD in people with type 2 diabetes.
In this post-hoc analysis of 2977 type 2 diabetes participants from the ACCORD MIND trial, we applied the causal forest and causal tree algorithms to identify the effect modifier of intensive glucose control in delaying CFD from 68 variables (demographics, disease history, medications, vitals and baseline biomarkers). The exposure was intensive versus standard glucose control (HbA1c <6.0% vs. 7.0%-7.9%). The main outcome was cognitive function changes from baseline to the 40th month follow-up, which were evaluated using the digit symbol substitution test, Rey auditory verbal learning test, mini-mental state examination and Stroop test. We used Cohen's d, a measure of standardized difference, to quantify the effect size of intensive glucose control on delaying CFD.
Among all the baseline characteristics, renal function was the most significant effect modifier. Participants with urinary albumin levels <0.4 mg/dl [absolute function change (AFC): 0.51 in mini-mental state examination, 95% confidence interval (CI): 0.04, 0.98, Cohen's d: 0.25] had slower CFD with intensive glucose control. Patients with preserved renal function (estimated glomerular filtration rate between 60 and 90 ml/min/1.73 m) were associated with small benefits (AFC: 1.28 in Stroop, 95% CI: 0.28, 2.27, Cohen's d: 0.12) when undergoing intensive glucose control. Conversely, participants with an estimated glomerular filtration rate <60 ml/min/1.73 m (AFC: -0.57 in the Rey auditory verbal learning test, 95% CI: -1.09, -0.05, Cohen's d: -0.30) exhibited faster CFD when undergoing intensive glucose control. Participants who were <60 years old showed a significant benefit from intensive glucose control in delaying CFD (AFC: 1.08 in the digit symbol substitution test, 95% CI: 0.06, 2.10, Cohen's d: 0.13). All p < .05.
Our findings linked renal function with the benefits of intensive glucose control in delaying CFD, informing personalized HbA1c goals for those with diabetes and at risk of CFD.
糖代谢紊乱加速认知能力下降。强化血糖控制可能有助于延缓或预防认知功能下降(CFD)。我们旨在确定患者特征如何影响强化血糖控制[糖化血红蛋白(HbA1c)<6.0%]对 2 型糖尿病患者 CFD 延迟的影响。
在 ACCORD MIND 试验的 2977 名 2 型糖尿病患者的这项事后分析中,我们应用因果森林和因果树算法来确定强化血糖控制对 CFD 延迟的影响修饰因子,该影响来自 68 个变量(人口统计学、疾病史、药物、生命体征和基线生物标志物)。暴露是强化血糖控制(HbA1c<6.0%)与标准血糖控制(HbA1c 7.0%-7.9%)之间的差异。主要结局是从基线到第 40 个月随访的认知功能变化,使用数字符号替换测试、 Rey 听觉言语学习测试、简易精神状态检查和 Stroop 测试进行评估。我们使用 Cohen's d,一种衡量标准化差异的指标,来量化强化血糖控制对延缓 CFD 的影响大小。
在所有基线特征中,肾功能是最重要的影响修饰因子。尿白蛋白水平<0.4mg/dl 的患者[简易精神状态检查的绝对功能变化(AFC):0.51,95%置信区间(CI):0.04,0.98,Cohen's d:0.25]强化血糖控制后 CFD 进展较慢。肾小球滤过率在 60 至 90ml/min/1.73m 之间的肾功能正常的患者强化血糖控制后获益较小(Stroop 测试的 AFC:1.28,95%CI:0.28,2.27,Cohen's d:0.12)。相反,肾小球滤过率<60ml/min/1.73m 的患者[Rey 听觉言语学习测试的 AFC:-0.57,95%CI:-1.09,-0.05,Cohen's d:-0.30]强化血糖控制后 CFD 进展更快。年龄<60 岁的患者强化血糖控制对延缓 CFD 有显著获益(数字符号替换测试的 AFC:1.08,95%CI:0.06,2.10,Cohen's d:0.13)。所有 p<0.05。
我们的研究结果将肾功能与强化血糖控制对延缓 CFD 的益处联系起来,为那些患有糖尿病和有 CFD 风险的患者提供个性化的 HbA1c 目标。